shutterstock_1349460623_pavel_kapysh

Pavel Kapysh / Shutterstock.com

1 March 2022Big PharmaMuireann Bolger

Ono sues AstraZeneca over antibody patents

Japan-based Ono Pharmaceuticals has sued AstraZeneca, accusing the US pharma company of infringing patents covering an antibody used in cancer treatment.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

AstraZeneca, MSD sue MSN and Sandoz over Calquence generics

8 February 2022 AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents.

Cancer centre sues BMS and Ono over alleged patent exploitation

25 June 2019 Boston-based Dana-Farber Cancer Institute is seeking a share of the $1.6 billion in licensing revenue that BMS and Ono Pharmaceutical Co have allegedly received from six immunotherapy patents.

More on this story

AstraZeneca, MSD sue MSN and Sandoz over Calquence generics

8 February 2022 AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents.

Cancer centre sues BMS and Ono over alleged patent exploitation

25 June 2019 Boston-based Dana-Farber Cancer Institute is seeking a share of the $1.6 billion in licensing revenue that BMS and Ono Pharmaceutical Co have allegedly received from six immunotherapy patents.

More on this story

AstraZeneca, MSD sue MSN and Sandoz over Calquence generics

8 February 2022 AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents.

Cancer centre sues BMS and Ono over alleged patent exploitation

25 June 2019 Boston-based Dana-Farber Cancer Institute is seeking a share of the $1.6 billion in licensing revenue that BMS and Ono Pharmaceutical Co have allegedly received from six immunotherapy patents.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB

Lewis Roca promotes tech expert to managing partner

Panitch Schwarze brings in molecular biologist

US targets ‘product hopping’ with biologic litigation curbs

UPC confirms validity of Edwards Lifesciences heart valve tech patent

ITC concludes row over biotech lab equipment between US and German rivals

UKIPO launches ‘revolutionary’ patent filing and AI tool

USPTO clarifies AI's role in patent eligibility